Acute promyelocytic leukemia: Difference between revisions

Jump to navigation Jump to search
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
No edit summary
Line 1: Line 1:
__NOTOC__
{{DiseaseDisorder infobox |
{{DiseaseDisorder infobox |
   Name          = Acute promyelocytic leukemia |
   Name          = Acute promyelocytic leukemia |
Line 15: Line 16:
{{CMG}}
{{CMG}}


 
{{SK}} Acute progranulocytic leukemia; APL; AML with t(15;17)(q22;q12); PML-RARA and variants; FAB subtype M3 and M3 variant;


==Overview==
==Overview==
'''Acute promyelocytic leukemia''' is a subtype of [[acute myelogenous leukemia]] (AML), a [[cancer]] of the [[blood]] and [[bone marrow]]. It is also known as '''acute progranulocytic leukemia'''; '''APL'''; '''AML with t(15;17)(q22;q12)''', '''PML-RARA and variants'''; '''FAB subtype M3 and M3 variant'''.
'''Acute promyelocytic leukemia''' is a subtype of [[acute myelogenous leukemia]] (AML), a [[cancer]] of the [[blood]] and [[bone marrow]].


In APL, there is an abnormal accumulation of immature [[granulocytes]] called promyelocytes.  The disease is characterized by a [[chromosomal translocation]] involving the [[retinoic acid receptor]] alpha (''RARα'' or ''RARA'') gene and is unique from other forms of AML in its responsiveness to [[ATRA|all ''trans'' retinoic acid]] (ATRA) therapy.
In APL, there is an abnormal accumulation of immature [[granulocytes]] called promyelocytes.  The disease is characterized by a [[chromosomal translocation]] involving the [[retinoic acid receptor]] alpha (''RARα'' or ''RARA'') gene and is unique from other forms of AML in its responsiveness to [[ATRA|all ''trans'' retinoic acid]] (ATRA) therapy.
Line 37: Line 38:
Acute promyelocytic leukemia represents 5-8% of AML in adults. The median age is approximately 40 years, which is considerably younger than the other subtypes of AML (70 years).  The incidence is increased in patients originated in Latin American countries.(Douer ''et al.'')
Acute promyelocytic leukemia represents 5-8% of AML in adults. The median age is approximately 40 years, which is considerably younger than the other subtypes of AML (70 years).  The incidence is increased in patients originated in Latin American countries.(Douer ''et al.'')


==Pathogenesis==
==Pathophysiology==
Acute promyelocytic leukemia is characterized by chromosomal translocation involving the retinoic acid receptor-alpha gene on chromosome 17 (''RARα'').  In 95% of cases of APL, retinoic acid receptor-alpha (''RARα'') gene on chromosome 17 is involved in a reciprocal translocation with the promyelocytic leukemia gene (''PML'') on chromosome 15, a translocation denoted as t(15;17)(q22;q12).  
Acute promyelocytic leukemia is characterized by chromosomal translocation involving the retinoic acid receptor-alpha gene on chromosome 17 (''RARα'').  In 95% of cases of APL, retinoic acid receptor-alpha (''RARα'') gene on chromosome 17 is involved in a reciprocal translocation with the promyelocytic leukemia gene (''PML'') on chromosome 15, a translocation denoted as t(15;17)(q22;q12).  



Revision as of 21:27, 12 September 2012

Template:DiseaseDisorder infobox

WikiDoc Resources for Acute promyelocytic leukemia

Articles

Most recent articles on Acute promyelocytic leukemia

Most cited articles on Acute promyelocytic leukemia

Review articles on Acute promyelocytic leukemia

Articles on Acute promyelocytic leukemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Acute promyelocytic leukemia

Images of Acute promyelocytic leukemia

Photos of Acute promyelocytic leukemia

Podcasts & MP3s on Acute promyelocytic leukemia

Videos on Acute promyelocytic leukemia

Evidence Based Medicine

Cochrane Collaboration on Acute promyelocytic leukemia

Bandolier on Acute promyelocytic leukemia

TRIP on Acute promyelocytic leukemia

Clinical Trials

Ongoing Trials on Acute promyelocytic leukemia at Clinical Trials.gov

Trial results on Acute promyelocytic leukemia

Clinical Trials on Acute promyelocytic leukemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Acute promyelocytic leukemia

NICE Guidance on Acute promyelocytic leukemia

NHS PRODIGY Guidance

FDA on Acute promyelocytic leukemia

CDC on Acute promyelocytic leukemia

Books

Books on Acute promyelocytic leukemia

News

Acute promyelocytic leukemia in the news

Be alerted to news on Acute promyelocytic leukemia

News trends on Acute promyelocytic leukemia

Commentary

Blogs on Acute promyelocytic leukemia

Definitions

Definitions of Acute promyelocytic leukemia

Patient Resources / Community

Patient resources on Acute promyelocytic leukemia

Discussion groups on Acute promyelocytic leukemia

Patient Handouts on Acute promyelocytic leukemia

Directions to Hospitals Treating Acute promyelocytic leukemia

Risk calculators and risk factors for Acute promyelocytic leukemia

Healthcare Provider Resources

Symptoms of Acute promyelocytic leukemia

Causes & Risk Factors for Acute promyelocytic leukemia

Diagnostic studies for Acute promyelocytic leukemia

Treatment of Acute promyelocytic leukemia

Continuing Medical Education (CME)

CME Programs on Acute promyelocytic leukemia

International

Acute promyelocytic leukemia en Espanol

Acute promyelocytic leukemia en Francais

Business

Acute promyelocytic leukemia in the Marketplace

Patents on Acute promyelocytic leukemia

Experimental / Informatics

List of terms related to Acute promyelocytic leukemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Acute progranulocytic leukemia; APL; AML with t(15;17)(q22;q12); PML-RARA and variants; FAB subtype M3 and M3 variant;

Overview

Acute promyelocytic leukemia is a subtype of acute myelogenous leukemia (AML), a cancer of the blood and bone marrow.

In APL, there is an abnormal accumulation of immature granulocytes called promyelocytes. The disease is characterized by a chromosomal translocation involving the retinoic acid receptor alpha (RARα or RARA) gene and is unique from other forms of AML in its responsiveness to all trans retinoic acid (ATRA) therapy.

Signs and symptoms

Signs and symptoms of acute promyelocytic leukemia are similar to other forms of AML. Symptoms include fever, fatigue, weight loss or loss of appetite, shortness of breath with exertion, anemia, easy bruising or bleeding, petechiae (flat, pin-head sized spots under the skin caused by bleeding), bone pain and joint pain and persistent or frequent infections.[8]

The accumulation of promyelocytes in the bone marrow results in a reduction in the production of normal red blood cells and platelets resulting in anemia and thrombocytopenia. Either leukopenia (low white cell count) or leukocytosis (high white cell count) may be observed in the peripheral blood.

Symptoms include:

  • Fatigue, weakness, shortness of breath (from anemia)
  • Easy bruising and bleeding (from thrombocytopenia and coagulopathy)
  • Fever and infection (from lack of normal white blood cells)

In addition, acute promyelocytic leukemia is frequently associated with bleeding caused by disseminated intravascular coagulation (DIC).

Epidemiology

Acute promyelocytic leukemia represents 5-8% of AML in adults. The median age is approximately 40 years, which is considerably younger than the other subtypes of AML (70 years). The incidence is increased in patients originated in Latin American countries.(Douer et al.)

Pathophysiology

Acute promyelocytic leukemia is characterized by chromosomal translocation involving the retinoic acid receptor-alpha gene on chromosome 17 (RARα). In 95% of cases of APL, retinoic acid receptor-alpha (RARα) gene on chromosome 17 is involved in a reciprocal translocation with the promyelocytic leukemia gene (PML) on chromosome 15, a translocation denoted as t(15;17)(q22;q12).

Four other gene rearrangements have been described in APL fusing RARα to promyelocytic leukemia zinc finger (PLZF), nucleophosmin (NPM), nuclear matrix associated (NUMA), or signal transducer and activator of transcription 5b (STAT5B) genes.

The resultant fusion proteins disrupt the function of RARα which blocks the normal maturation of granulocytes. Although the chromosomal translocation involving RARα is believed to be the initiating event, additional mutations are required for the development of leukemia.

Diagnosis

Acute promyelocytic leukemia can be distinguished from other types of AML based on morphologic examination of a bone marrow biopsy or aspirate. Definitive diagnosis requires testing for the RARα fusion gene. This may be done by polymerase chain reaction (PCR), fluorescent in situ hybridization (FISH), or conventional cytogenetics of peripheral blood or bone marrow.

Monitoring for relapse using PCR tests for RARα allows early re-treatment which is successful in many instances.

Treatment

APL is unique among the leukemias distinguished by its sensitivity to all-trans retinoic acid (ATRA), a derivative of vitamin A. Treatment with ATRA causes differentiation of the immature leukemic promyelocytes into mature granulocytes. ATRA is typically combined with anthracycline based chemotherapy resulting in a clinical remission in approximately 90% of patients.

ATRA therapy is associated with the unique side effect of retinoic acid syndrome. This is associated with the development of dyspnea, fever, weight gain, peripheral edema and is treated with dexamethasone. The etiology of retinoic acid syndrome has been attributed to capillary leak syndrome from cytokine release from the differentiating promyelocytes.

Treatment options for patients with relapsed disease include arsenic trioxide and allogeneic stem cell transplant.

References

  • Kumar, Vinay, Abul Abbas, and Nelson Fausto. Robbins and Cotran Pathologic Basis of Disease, 7th ed. (2004). ISBN 81-8147-528-3
  • Sacher, Ronald A. and Richard A. McPherson. Wildman's Clinical Interpretation of Laboratory Tests, 11th ed. (2000). ISBN 0-8036-0270-7
  • Dan Douer, et al. British Journal of Haematology, vol. 122, pp. 563, Aug. 2003
  • Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide, N Engl J Med. 1998 Nov 5;339(19):1341-8.

de:Promyelozytenleukämie

Template:WikiDoc Sources